expertise on the research innovation, development ...€¦ · Your Only Choice ! Neptune...
8
Your Only Choice !
Transcript of expertise on the research innovation, development ...€¦ · Your Only Choice ! Neptune...
Your Only Choice !
Neptune Technologies & Bioressources has gained over the last decade, significant expertise on the research, innovation, development, scientific validation and commercialization of proprietary/patent protected natural health ingredients with worldwide regulatory approvals.
The Company pursues market opportunities in nutraceutical and pharmaceutical industries focusing on growing therapeutic indications such as heart, joint and cognitive health.
Neptune is the pioneer in the research, development and commercialization of krill extracts for human health benefits. The Company’s first product is the globally acknowledged
Neptune Krill Oil (NKO®).
NeptuNe teChNOlOgies & BiOressOurCes iNC.
www.neptunebiotech.com Tél.: +1 450 687-2262 Email: [email protected]
• Identify & Exploit Marine Biomass
• Research & Develop Novel Marine Bioactive Ingredients and Customized Formulations
• Validate Superiority, Safety & Effectiveness
• Protect Intellectual Property
• Commercialize / Pursue opportunities in Nutraceutical & Pharmaceutical Markets
• Develop Strategic Partnerships with industry leaders
Mission
Markets• Dietary Supplements
• Complementary Medicine
• Functional Food
• Pharmaceuticals via subsidiaries – Acasti Pharma Inc.: Cardiovascular – NeuroBioPharm Inc.: Neurological
• Cosmeceuticals / Cosmetics
• Animal Nutrition / Pet Foods
extraction platform
Krill
• Most abundant marine biomass
• Zooplankton
• Bottom of the food chain
• Breeding in the pure uncontaminated deep sea waters
sustainability:
• Standing stock of more than 500 million tons
• Precautionary catch limit of Antarctic krill set by the CCAMLR* reviewed annually.
• Under exploited marine biomass: – Less than 0.02% is actually harvested
* CCAMLR: Commission for the Conservation of Antarctic Marine Living Resources.
teChNiCal Features
Abundant Source
• GMP Nutraceutical (NHPD / Health Canada)
• Proprietary / Patented extraction platform
• Exploit the full value of marine biomass
• Preserve biological properties
• Cold temperature / Inert environment
• Food grade organic solvent (undetected in final product)
• R&D and Laboratory Facilities in house
• Fine Point Production Technology
NeptuNe Krill Oil (NKO®
)
Brunswick Laboratories, 6 Thachet Lane, Wareham, MA 02571
Boxin Ou, Principal Research Scientist U.S. Departement of Agriculture (http://www.ars.usda.gouv/nutrientdata)
8
11
51
58
96
147
378
Fish Oil
co-q10
Astaxanthin
Lycopene
Blueberry
Cranberry
Elderberry
4003002001000
66
OR
AC
Va
lue nko® Astaxanthin:
> 90% esterified
A proprietary marine extract, offering a unique composition of EPA & DHA functionalized on PHOSPHOLIPIDS and esterified ASTAXANTHIN.
Patented composition
highest Omega-3 Bioavailability
Superior Antioxidant Potency
Design: Human Study, Perspective, Randomized, Double BlindDosage: Standardized to 120 mg of EPA & DHA / dayresults: NKO® demonstrates a greater increase of Omega-3 Index
and provides higher bioavailability of EPA & DHA compared to other sources of Omega-3
*Omega-3 Index: New Risk Factor for cardiovascular diseases. Indicates the amount of EPA & DHA in red blood cells versus total fatty acids. Closer to 8 = lower risk for cardio diseases
Baseline 8 weeks 16 weeks
6,67*
5,955,98
6,27
5,93
6,056,2
5,80
6,69*
5,16
5,675,81*
7
5
6,6
6,2
5,8
5,4
Omega-3 Index*N = 48
Om
eg
a-3
Ind
ex
Ethyl Esters
Fish Oil
NKO®-like Blend
Oxygen radical absorption Capacity
Your Only Choice !
Neptune Technologies & Bioressources has gained over the last decade, significant expertise on the research, innovation, development, scientific validation and commercialization of proprietary/patent protected natural health ingredients with worldwide regulatory approvals.
The Company pursues market opportunities in nutraceutical and pharmaceutical industries focusing on growing therapeutic indications such as heart, joint and cognitive health.
Neptune is the pioneer in the research, development and commercialization of krill extracts for human health benefits. The Company’s first product is the globally acknowledged
Neptune Krill Oil (NKO®).
NeptuNe teChNOlOgies & BiOressOurCes iNC.
www.neptunebiotech.com Tél.: +1 450 687-2262 Email: [email protected]
• Identify & Exploit Marine Biomass
• Research & Develop Novel Marine Bioactive Ingredients and Customized Formulations
• Validate Superiority, Safety & Effectiveness
• Protect Intellectual Property
• Commercialize / Pursue opportunities in Nutraceutical & Pharmaceutical Markets
• Develop Strategic Partnerships with industry leaders
Mission
Markets• Dietary Supplements
• Complementary Medicine
• Functional Food
• Pharmaceuticals via subsidiaries – Acasti Pharma Inc.: Cardiovascular – NeuroBioPharm Inc.: Neurological
• Cosmeceuticals / Cosmetics
• Animal Nutrition / Pet Foods
www.neptunebiotech.com Tél.: +1 450 687-2262 Email: [email protected]
Pharmaceuticals via subsidiaries– Acasti Pharma Inc.: Cardiovascular– NeuroBioPharm Inc.: Neurological
Cosmetics
Pet Foods
extraction platform
Krill
• Most abundant marine biomass
• Zooplankton
• Bottom of the food chain
• Breeding in the pure uncontaminated deep sea waters
sustainability:
• Standing stock of more than 500 million tons
• Precautionary catch limit of Antarctic krill set by the CCAMLR* reviewed annually.
• Under exploited marine biomass: – Less than 0.02% is actually harvested
* CCAMLR: Commission for the Conservation of Antarctic Marine Living Resources.
teChNiCal Features
Abundant Source
• GMP Nutraceutical (NHPD / Health Canada)
• Proprietary / Patented extraction platform
• Exploit the full value of marine biomass
• Preserve biological properties
• Cold temperature / Inert environment
• Food grade organic solvent (undetected in final product)
• R&D and Laboratory Facilities in house
• Fine Point Production Technology
NeptuNe Krill Oil (NKO®
)
Brunswick Laboratories, 6 Thachet Lane, Wareham, MA 02571
Boxin Ou, Principal Research Scientist U.S. Departement of Agriculture (http://www.ars.usda.gouv/nutrientdata)
8
11
51
58
96
147
378
Fish Oil
co-q10
Astaxanthin
Lycopene
Blueberry
Cranberry
Elderberry
4003002001000
66
OR
AC
Va
lue nko® Astaxanthin:
> 90% esterified
A proprietary marine extract, offering a unique composition of EPA & DHA functionalized on PHOSPHOLIPIDS and esterified ASTAXANTHIN.
Patented composition
highest Omega-3 Bioavailability
Superior Antioxidant Potency
Design: Human Study, Perspective, Randomized, Double BlindDosage: Standardized to 120 mg of EPA & DHA / dayresults: NKO® demonstrates a greater increase of Omega-3 Index
and provides higher bioavailability of EPA & DHA compared to other sources of Omega-3
*Omega-3 Index: New Risk Factor for cardiovascular diseases. Indicates the amount of EPA & DHA in red blood cells versus total fatty acids. Closer to 8 = lower risk for cardio diseases
Baseline 8 weeks 16 weeks
6,67*
5,955,98
6,27
5,93
6,056,2
5,80
6,69*
5,16
5,675,81*
7
5
6,6
6,2
5,8
5,4
Omega-3 Index*N = 48
Om
eg
a-3
Ind
ex
Ethyl Esters
Fish Oil
NKO®-like Blend
Oxygen radical absorption Capacity
PArAmETErs sTANDArD sPECifiCATiONsPhysICal PRoPERtIEs
Appearance Red viscous oil
Odor Light shrimp
Humidity ‹ 0.9%
Viscosity 600 ± 150 cP
PhosPholIPIDs
Total Phospholipids › 40%
% PL* with EPA and / or DHA › 70%
% epa & Dha on pl › 55%
Fatty aCID PRoFIlE
total Omega-3 › 30%
epa › 15%
Dha › 9%
EPA g / 100g (expressed as FA) › 12%
DHA g / 100g (expressed as FA) › 7.5%
Total Omega-6 ‹ 1.7%
Total Omega-9 › 9.0%
total trans Fat ‹ 0.1%
antIoxIDants
pigments
Esterified Astaxanthin › 125 mg / 100g
Vitamins
Vitamin A › 250 IU / g
Alpha-Tocopherol › 0.6 IU / g
stabIlIty InDExEs
Saponification value 180.0 ± 10.0 mg KOH / g
Iodine value 145.0 ± 15.0 g l2 / 100g
p-Anisidine value (A) ‹ 2.1
Peroxide value (PV) ‹ 0.2 mEq peroxide / kg
Totox value (2PV+A) ‹ 2.5
MICRobIal analysIs
Total aerobic count ‹ 100 CFU / g
Total coliforms ‹ 10 CFU / g
E.coli Absence
Yeast & Molds ‹ 100 CFU / g
Staphilococcus aureus Absence
Listeria monocytogenes Absence
Pseudomonas aeruginosa Absence
Salmonelia spp. Absence
allERgEns
May contain traces of seafood protein
no REFlux.
prODuCt prOFile
* PL: Phospholipids
cLinicALLy ProVEn BeNeFits at lOw DailY DOse
Cardiovascular Health
After 3 months
50
40
30
20
10
0
-10
-20
-30
-40
Pe
rce
nt
(%) C
ha
ng
e
(PMID: 15656713)
+9.1
+13.0
-4.6
-11.5
+0.1
-3.3
+43.3
+4.2
-33.9
-6.3-3.2
-9.9
-13.6
-5.9
Placebo Omega-3 : Fish oil (18:12) 3.0 g/day 1.0 - 1.5 g/day
Cholesterol Triglycerides LDL GlucoseHDL
N = 120
+4.0
EvAluATiON Of THE EffECTs Of NKO® ON CHrONiC iNflAmATiON AND ArTHriTiC symPTOmsJoint Health
60
50
40
30
20
10
0
-10
-20
-30
-40
30
20
10
0
-10
-20
-30
-40
-9.4
-28.9-25.7
-38.4
-20.3 -26.1
-39.1
-22.8
-11.1
-29.3
+6.7
+17.5
+4.2
-35.9
-0.6 -0.7 -1.34-6.7
Rapid Effect At Low Dose
InflammationEffect on C-Reactive Protein
Pe
rce
nt
(%) C
ha
ng
e
Pe
rce
nt
(%) C
ha
ng
e (
WO
MA
C S
CO
RE
)
N = 90
N = 90
+15.7
+32.1
+25.1
-19.3
-29.7 -30.9
7 days 14 days 30 days
(PMID 2007: 17353582)Osteoarthritis
7 days 14 days 30 days 30 days 30 days14 days 14 days7 days 7 days
Pain Stiffness Functional Impairment
Placebo 300 mg/day
Design: Human Study, Prospective, Randomized, Double Blind NKO® Dosage: 300mg / dayresults: NKO® Significantly reduced inflammation (C-reactive Protein) and alleviated symptoms caused by osteoarthritis.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON ADulT ADHD*
Design: Human Pilot Study, Open LabelNKO®: 500mg / dayresults: NKO® is safe and effective for the management of adult ADHD.
* Attention Deficit and Hyperactivity Disorder
: p < 0.05
Per
cen
t (%
) Ch
an
ge
Cognitive Function
Significant Impact on Adult ADHDAfter 3 and 6 Months
70
60
50
40
30
20
10
0
-10
Concentration Focus Planning Skills
+46.7
+60.2
+49.8 +48.8 +47.8 +47.8
N = 30
500 mg/day After 3 Months
500 mg/day After 6 Months
EvAluATiON Of THE EffECTs Of NKO® ON THE mANAgEmENT Of Pms*
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: 2g / day, 8 days prior to and 2 days during menstruation
results: NKO® significantly reduced physical and emotional symptoms related to PMS
* PMS: Premenstrual Symptoms
: p < 0.05
Pe
rce
nt
(%) C
an
ge
Women’s Health
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
N = 70
Physical & Emotional Effects on PMSAfter 3 Months
Bloating WeightGain
AbdominalPain
Swelling Stress Depression IrritabilityBreastTenderness
Over-whelmeness
Joint Pain
-10.0
-21.0-15.0
-29.0
-20.0
-34.0
-25.0
-37.0
-12.0
-38.0
-13.0
-39.0
-15.0
-42.0
-4.0
-42.0
-10.0
-47.0
-23.0
-64.0
(PIMD: 12777162)
Omega-3 : Fish oil (18:12) 2 g/day8 days prior to menstruation2 days during
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: NKO® = 1.0-1.5g / day, 0.5g / day for maintenance Fish oil = 3 g / day
results: NKO® significantly reduced total cholesterol, LDL and triglycerides and increased HDL levels. NKO® is significantly more efficient than fish oil for reducing cholesterol, LDL and TG and increasing HDL.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON THE CliNiCAl COursE Of HyPErliPiDEmiA
AgENCy APPrOvAl COuNTry
fda (Food & Drug Association)GRAS (Generally Reconized as Safe)NDI (New Dietary Ingredient)
United States
nhpd (Natural Health Products Directorate) NPN (Natural Product Number) canada
efsa (European Food & Safety Authority) Novel Food & PARNUTS european union
ifanca (Islamic Food and Nutrition Countil of America) Halal Certification islamic Countries
tga (Therapeutic Goods Administration) Complementry Medecine australia
marine phospholipids bonding EPA & DHA & Antioxidants
superior Bioavailability
Only Krill Oil with Clinically Proven Health Benefits at market DRI
validated safety & stability
superior Antioxidant Potency Premium Choice of market leaders
No Trans Fat / No Reflux Non detectable:
Heavy metals, Dioxins, allergens
Worldwide issued Patents (Process, Composition & use)
gmP manufactured
multinational regulatory Approval
comPETiTiVE ADVAnTAgES
partner with excellence!
commercialize Worldwide
PArAmETErs sTANDArD sPECifiCATiONsPhysICal PRoPERtIEs
Appearance Red viscous oil
Odor Light shrimp
Humidity ‹ 0.9%
Viscosity 600 ± 150 cP
PhosPholIPIDs
Total Phospholipids › 40%
% PL* with EPA and / or DHA › 70%
% epa & Dha on pl › 55%
Fatty aCID PRoFIlE
total Omega-3 › 30%
epa › 15%
Dha › 9%
EPA g / 100g (expressed as FA) › 12%
DHA g / 100g (expressed as FA) › 7.5%
Total Omega-6 ‹ 1.7%
Total Omega-9 › 9.0%
total trans Fat ‹ 0.1%
antIoxIDants
pigments
Esterified Astaxanthin › 125 mg / 100g
Vitamins
Vitamin A › 250 IU / g
Alpha-Tocopherol › 0.6 IU / g
stabIlIty InDExEs
Saponification value 180.0 ± 10.0 mg KOH / g
Iodine value 145.0 ± 15.0 g l2 / 100g
p-Anisidine value (A) ‹ 2.1
Peroxide value (PV) ‹ 0.2 mEq peroxide / kg
Totox value (2PV+A) ‹ 2.5
MICRobIal analysIs
Total aerobic count ‹ 100 CFU / g
Total coliforms ‹ 10 CFU / g
E.coli Absence
Yeast & Molds ‹ 100 CFU / g
Staphilococcus aureus Absence
Listeria monocytogenes Absence
Pseudomonas aeruginosa Absence
Salmonelia spp. Absence
allERgEns
May contain traces of seafood protein
no REFlux.
prODuCt prOFile
* PL: Phospholipids
cLinicALLy ProVEn BeNeFits at lOw DailY DOse
Cardiovascular Health
After 3 months
50
40
30
20
10
0
-10
-20
-30
-40
Pe
rce
nt
(%) C
ha
ng
e
(PMID: 15656713)
+9.1
+13.0
-4.6
-11.5
+0.1
-3.3
+43.3
+4.2
-33.9
-6.3-3.2
-9.9
-13.6
-5.9
Placebo Omega-3 : Fish oil (18:12) 3.0 g/day 1.0 - 1.5 g/day
Cholesterol Triglycerides LDL GlucoseHDL
N = 120
+4.0
EvAluATiON Of THE EffECTs Of NKO® ON CHrONiC iNflAmATiON AND ArTHriTiC symPTOmsJoint Health
60
50
40
30
20
10
0
-10
-20
-30
-40
30
20
10
0
-10
-20
-30
-40
-9.4
-28.9-25.7
-38.4
-20.3 -26.1
-39.1
-22.8
-11.1
-29.3
+6.7
+17.5
+4.2
-35.9
-0.6 -0.7 -1.34-6.7
Rapid Effect At Low Dose
InflammationEffect on C-Reactive Protein
Pe
rce
nt
(%) C
ha
ng
e
Pe
rce
nt
(%) C
ha
ng
e (
WO
MA
C S
CO
RE
)
N = 90
N = 90
+15.7
+32.1
+25.1
-19.3
-29.7 -30.9
7 days 14 days 30 days
(PMID 2007: 17353582)Osteoarthritis
7 days 14 days 30 days 30 days 30 days14 days 14 days7 days 7 days
Pain Stiffness Functional Impairment
Placebo 300 mg/day
Design: Human Study, Prospective, Randomized, Double Blind NKO® Dosage: 300mg / dayresults: NKO® Significantly reduced inflammation (C-reactive Protein) and alleviated symptoms caused by osteoarthritis.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON ADulT ADHD*
Design: Human Pilot Study, Open LabelNKO®: 500mg / dayresults: NKO® is safe and effective for the management of adult ADHD.
* Attention Deficit and Hyperactivity Disorder
: p < 0.05
Per
cen
t (%
) Ch
an
ge
Cognitive Function
Significant Impact on Adult ADHDAfter 3 and 6 Months
70
60
50
40
30
20
10
0
-10
Concentration Focus Planning Skills
+46.7
+60.2
+49.8 +48.8 +47.8 +47.8
N = 30
500 mg/day After 3 Months
500 mg/day After 6 Months
EvAluATiON Of THE EffECTs Of NKO® ON THE mANAgEmENT Of Pms*
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: 2g / day, 8 days prior to and 2 days during menstruation
results: NKO® significantly reduced physical and emotional symptoms related to PMS
* PMS: Premenstrual Symptoms
: p < 0.05
Pe
rce
nt
(%) C
an
ge
Women’s Health
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
N = 70
Physical & Emotional Effects on PMSAfter 3 Months
Bloating WeightGain
AbdominalPain
Swelling Stress Depression IrritabilityBreastTenderness
Over-whelmeness
Joint Pain
-10.0
-21.0-15.0
-29.0
-20.0
-34.0
-25.0
-37.0
-12.0
-38.0
-13.0
-39.0
-15.0
-42.0
-4.0
-42.0
-10.0
-47.0
-23.0
-64.0
(PIMD: 12777162)
Omega-3 : Fish oil (18:12) 2 g/day8 days prior to menstruation2 days during
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: NKO® = 1.0-1.5g / day, 0.5g / day for maintenance Fish oil = 3 g / day
results: NKO® significantly reduced total cholesterol, LDL and triglycerides and increased HDL levels. NKO® is significantly more efficient than fish oil for reducing cholesterol, LDL and TG and increasing HDL.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON THE CliNiCAl COursE Of HyPErliPiDEmiA
AgENCy APPrOvAl COuNTry
fda (Food & Drug Association)GRAS (Generally Reconized as Safe)NDI (New Dietary Ingredient)
United States
nhpd (Natural Health Products Directorate) NPN (Natural Product Number) canada
efsa (European Food & Safety Authority) Novel Food & PARNUTS european union
ifanca (Islamic Food and Nutrition Countil of America) Halal Certification islamic Countries
tga (Therapeutic Goods Administration) Complementry Medecine australia
marine phospholipids bonding EPA & DHA & Antioxidants
superior Bioavailability
Only Krill Oil with Clinically Proven Health Benefits at market DRI
validated safety & stability
superior Antioxidant Potency Premium Choice of market leaders
No Trans Fat / No Reflux Non detectable:
Heavy metals, Dioxins, allergens
Worldwide issued Patents (Process, Composition & use)
gmP manufactured
multinational regulatory Approval
comPETiTiVE ADVAnTAgES
partner with excellence!
commercialize Worldwide
PArAmETErs sTANDArD sPECifiCATiONsPhysICal PRoPERtIEs
Appearance Red viscous oil
Odor Light shrimp
Humidity ‹ 0.9%
Viscosity 600 ± 150 cP
PhosPholIPIDs
Total Phospholipids › 40%
% PL* with EPA and / or DHA › 70%
% epa & Dha on pl › 55%
Fatty aCID PRoFIlE
total Omega-3 › 30%
epa › 15%
Dha › 9%
EPA g / 100g (expressed as FA) › 12%
DHA g / 100g (expressed as FA) › 7.5%
Total Omega-6 ‹ 1.7%
Total Omega-9 › 9.0%
total trans Fat ‹ 0.1%
antIoxIDants
pigments
Esterified Astaxanthin › 125 mg / 100g
Vitamins
Vitamin A › 250 IU / g
Alpha-Tocopherol › 0.6 IU / g
stabIlIty InDExEs
Saponification value 180.0 ± 10.0 mg KOH / g
Iodine value 145.0 ± 15.0 g l2 / 100g
p-Anisidine value (A) ‹ 2.1
Peroxide value (PV) ‹ 0.2 mEq peroxide / kg
Totox value (2PV+A) ‹ 2.5
MICRobIal analysIs
Total aerobic count ‹ 100 CFU / g
Total coliforms ‹ 10 CFU / g
E.coli Absence
Yeast & Molds ‹ 100 CFU / g
Staphilococcus aureus Absence
Listeria monocytogenes Absence
Pseudomonas aeruginosa Absence
Salmonelia spp. Absence
allERgEns
May contain traces of seafood protein
no REFlux.
prODuCt prOFile
* PL: Phospholipids
cLinicALLy ProVEn BeNeFits at lOw DailY DOse
Cardiovascular Health
After 3 months
50
40
30
20
10
0
-10
-20
-30
-40
Pe
rce
nt
(%) C
ha
ng
e
(PMID: 15656713)
+9.1
+13.0
-4.6
-11.5
+0.1
-3.3
+43.3
+4.2
-33.9
-6.3-3.2
-9.9
-13.6
-5.9
Placebo Omega-3 : Fish oil (18:12) 3.0 g/day 1.0 - 1.5 g/day
Cholesterol Triglycerides LDL GlucoseHDL
N = 120
+4.0
EvAluATiON Of THE EffECTs Of NKO® ON CHrONiC iNflAmATiON AND ArTHriTiC symPTOmsJoint Health
60
50
40
30
20
10
0
-10
-20
-30
-40
30
20
10
0
-10
-20
-30
-40
-9.4
-28.9-25.7
-38.4
-20.3 -26.1
-39.1
-22.8
-11.1
-29.3
+6.7
+17.5
+4.2
-35.9
-0.6 -0.7 -1.34-6.7
Rapid Effect At Low Dose
InflammationEffect on C-Reactive Protein
Pe
rce
nt
(%) C
ha
ng
e
Pe
rce
nt
(%) C
ha
ng
e (
WO
MA
C S
CO
RE
)
N = 90
N = 90
+15.7
+32.1
+25.1
-19.3
-29.7 -30.9
7 days 14 days 30 days
(PMID 2007: 17353582)Osteoarthritis
7 days 14 days 30 days 30 days 30 days14 days 14 days7 days 7 days
Pain Stiffness Functional Impairment
Placebo 300 mg/day
Design: Human Study, Prospective, Randomized, Double Blind NKO® Dosage: 300mg / dayresults: NKO® Significantly reduced inflammation (C-reactive Protein) and alleviated symptoms caused by osteoarthritis.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON ADulT ADHD*
Design: Human Pilot Study, Open LabelNKO®: 500mg / dayresults: NKO® is safe and effective for the management of adult ADHD.
* Attention Deficit and Hyperactivity Disorder
: p < 0.05
Per
cen
t (%
) Ch
an
ge
Cognitive Function
Significant Impact on Adult ADHDAfter 3 and 6 Months
70
60
50
40
30
20
10
0
-10
Concentration Focus Planning Skills
+46.7
+60.2
+49.8 +48.8 +47.8 +47.8
N = 30
500 mg/day After 3 Months
500 mg/day After 6 Months
EvAluATiON Of THE EffECTs Of NKO® ON THE mANAgEmENT Of Pms*
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: 2g / day, 8 days prior to and 2 days during menstruation
results: NKO® significantly reduced physical and emotional symptoms related to PMS
* PMS: Premenstrual Symptoms
: p < 0.05
Pe
rce
nt
(%) C
an
ge
Women’s Health
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
N = 70
Physical & Emotional Effects on PMSAfter 3 Months
Bloating WeightGain
AbdominalPain
Swelling Stress Depression IrritabilityBreastTenderness
Over-whelmeness
Joint Pain
-10.0
-21.0-15.0
-29.0
-20.0
-34.0
-25.0
-37.0
-12.0
-38.0
-13.0
-39.0
-15.0
-42.0
-4.0
-42.0
-10.0
-47.0
-23.0
-64.0
(PIMD: 12777162)
Omega-3 : Fish oil (18:12) 2 g/day8 days prior to menstruation2 days during
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: NKO® = 1.0-1.5g / day, 0.5g / day for maintenance Fish oil = 3 g / day
results: NKO® significantly reduced total cholesterol, LDL and triglycerides and increased HDL levels. NKO® is significantly more efficient than fish oil for reducing cholesterol, LDL and TG and increasing HDL.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON THE CliNiCAl COursE Of HyPErliPiDEmiA
AgENCy APPrOvAl COuNTry
fda (Food & Drug Association)GRAS (Generally Reconized as Safe)NDI (New Dietary Ingredient)
United States
nhpd (Natural Health Products Directorate) NPN (Natural Product Number) canada
efsa (European Food & Safety Authority) Novel Food & PARNUTS european union
ifanca (Islamic Food and Nutrition Countil of America) Halal Certification islamic Countries
tga (Therapeutic Goods Administration) Complementry Medecine australia
marine phospholipids bonding EPA & DHA & Antioxidants
superior Bioavailability
Only Krill Oil with Clinically Proven Health Benefits at market DRI
validated safety & stability
superior Antioxidant Potency Premium Choice of market leaders
No Trans Fat / No Reflux Non detectable:
Heavy metals, Dioxins, allergens
Worldwide issued Patents (Process, Composition & use)
gmP manufactured
multinational regulatory Approval
comPETiTiVE ADVAnTAgES
partner with excellence!
commercialize Worldwide
PArAmETErs sTANDArD sPECifiCATiONsPhysICal PRoPERtIEs
Appearance Red viscous oil
Odor Light shrimp
Humidity ‹ 0.9%
Viscosity 600 ± 150 cP
PhosPholIPIDs
Total Phospholipids › 40%
% PL* with EPA and / or DHA › 70%
% epa & Dha on pl › 55%
Fatty aCID PRoFIlE
total Omega-3 › 30%
epa › 15%
Dha › 9%
EPA g / 100g (expressed as FA) › 12%
DHA g / 100g (expressed as FA) › 7.5%
Total Omega-6 ‹ 1.7%
Total Omega-9 › 9.0%
total trans Fat ‹ 0.1%
antIoxIDants
pigments
Esterified Astaxanthin › 125 mg / 100g
Vitamins
Vitamin A › 250 IU / g
Alpha-Tocopherol › 0.6 IU / g
stabIlIty InDExEs
Saponification value 180.0 ± 10.0 mg KOH / g
Iodine value 145.0 ± 15.0 g l2 / 100g
p-Anisidine value (A) ‹ 2.1
Peroxide value (PV) ‹ 0.2 mEq peroxide / kg
Totox value (2PV+A) ‹ 2.5
MICRobIal analysIs
Total aerobic count ‹ 100 CFU / g
Total coliforms ‹ 10 CFU / g
E.coli Absence
Yeast & Molds ‹ 100 CFU / g
Staphilococcus aureus Absence
Listeria monocytogenes Absence
Pseudomonas aeruginosa Absence
Salmonelia spp. Absence
allERgEns
May contain traces of seafood protein
no REFlux.
prODuCt prOFile
* PL: Phospholipids
cLinicALLy ProVEn BeNeFits at lOw DailY DOse
Cardiovascular Health
After 3 months
50
40
30
20
10
0
-10
-20
-30
-40
Pe
rce
nt
(%) C
ha
ng
e
(PMID: 15656713)
+9.1
+13.0
-4.6
-11.5
+0.1
-3.3
+43.3
+4.2
-33.9
-6.3-3.2
-9.9
-13.6
-5.9
Placebo Omega-3 : Fish oil (18:12) 3.0 g/day 1.0 - 1.5 g/day
Cholesterol Triglycerides LDL GlucoseHDL
N = 120
+4.0
EvAluATiON Of THE EffECTs Of NKO® ON CHrONiC iNflAmATiON AND ArTHriTiC symPTOmsJoint Health
60
50
40
30
20
10
0
-10
-20
-30
-40
30
20
10
0
-10
-20
-30
-40
-9.4
-28.9-25.7
-38.4
-20.3 -26.1
-39.1
-22.8
-11.1
-29.3
+6.7
+17.5
+4.2
-35.9
-0.6 -0.7 -1.34-6.7
Rapid Effect At Low Dose
InflammationEffect on C-Reactive Protein
Pe
rce
nt
(%) C
ha
ng
e
Pe
rce
nt
(%) C
ha
ng
e (
WO
MA
C S
CO
RE
)
N = 90
N = 90
+15.7
+32.1
+25.1
-19.3
-29.7 -30.9
7 days 14 days 30 days
(PMID 2007: 17353582)Osteoarthritis
7 days 14 days 30 days 30 days 30 days14 days 14 days7 days 7 days
Pain Stiffness Functional Impairment
Placebo 300 mg/day
Design: Human Study, Prospective, Randomized, Double Blind NKO® Dosage: 300mg / dayresults: NKO® Significantly reduced inflammation (C-reactive Protein) and alleviated symptoms caused by osteoarthritis.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON ADulT ADHD*
Design: Human Pilot Study, Open LabelNKO®: 500mg / dayresults: NKO® is safe and effective for the management of adult ADHD.
* Attention Deficit and Hyperactivity Disorder
: p < 0.05
Per
cen
t (%
) Ch
an
ge
Cognitive Function
Significant Impact on Adult ADHDAfter 3 and 6 Months
70
60
50
40
30
20
10
0
-10
Concentration Focus Planning Skills
+46.7
+60.2
+49.8 +48.8 +47.8 +47.8
N = 30
500 mg/day After 3 Months
500 mg/day After 6 Months
EvAluATiON Of THE EffECTs Of NKO® ON THE mANAgEmENT Of Pms*
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: 2g / day, 8 days prior to and 2 days during menstruation
results: NKO® significantly reduced physical and emotional symptoms related to PMS
* PMS: Premenstrual Symptoms
: p < 0.05
Pe
rce
nt
(%) C
an
ge
Women’s Health
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
N = 70
Physical & Emotional Effects on PMSAfter 3 Months
Bloating WeightGain
AbdominalPain
Swelling Stress Depression IrritabilityBreastTenderness
Over-whelmeness
Joint Pain
-10.0
-21.0-15.0
-29.0
-20.0
-34.0
-25.0
-37.0
-12.0
-38.0
-13.0
-39.0
-15.0
-42.0
-4.0
-42.0
-10.0
-47.0
-23.0
-64.0
(PIMD: 12777162)
Omega-3 : Fish oil (18:12) 2 g/day8 days prior to menstruation2 days during
Design: Human Study, Prospective, Randomized, Double Blind
Dosage: NKO® = 1.0-1.5g / day, 0.5g / day for maintenance Fish oil = 3 g / day
results: NKO® significantly reduced total cholesterol, LDL and triglycerides and increased HDL levels. NKO® is significantly more efficient than fish oil for reducing cholesterol, LDL and TG and increasing HDL.
: p < 0.05
EvAluATiON Of THE EffECTs Of NKO® ON THE CliNiCAl COursE Of HyPErliPiDEmiA
AgENCy APPrOvAl COuNTry
fda (Food & Drug Association)GRAS (Generally Reconized as Safe)NDI (New Dietary Ingredient)
United States
nhpd (Natural Health Products Directorate) NPN (Natural Product Number) canada
efsa (European Food & Safety Authority) Novel Food & PARNUTS european union
ifanca (Islamic Food and Nutrition Countil of America) Halal Certification islamic Countries
tga (Therapeutic Goods Administration) Complementry Medecine australia
marine phospholipids bonding EPA & DHA & Antioxidants
superior Bioavailability
Only Krill Oil with Clinically Proven Health Benefits at market DRI
validated safety & stability
superior Antioxidant Potency Premium Choice of market leaders
No Trans Fat / No Reflux Non detectable:
Heavy metals, Dioxins, allergens
Worldwide issued Patents (Process, Composition & use)
gmP manufactured
multinational regulatory Approval
comPETiTiVE ADVAnTAgES
partner with excellence!
commercialize Worldwide
Your Only Choice !
Neptune Technologies & Bioressources has gained over the last decade, significant expertise on the research, innovation, development, scientific validation and commercialization of proprietary/patent protected natural health ingredients with worldwide regulatory approvals.
The Company pursues market opportunities in nutraceutical and pharmaceutical industries focusing on growing therapeutic indications such as heart, joint and cognitive health.
Neptune is the pioneer in the research, development and commercialization of krill extracts for human health benefits. The Company’s first product is the globally acknowledged
Neptune Krill Oil (NKO®).
NeptuNe teChNOlOgies & BiOressOurCes iNC.
www.neptunebiotech.com Tél.: +1 450 687-2262 Email: [email protected]
• Identify & Exploit Marine Biomass
• Research & Develop Novel Marine Bioactive Ingredients and Customized Formulations
• Validate Superiority, Safety & Effectiveness
• Protect Intellectual Property
• Commercialize / Pursue opportunities in Nutraceutical & Pharmaceutical Markets
• Develop Strategic Partnerships with industry leaders
Mission
Markets• Dietary Supplements
• Complementary Medicine
• Functional Food
• Pharmaceuticals via subsidiaries – Acasti Pharma Inc.: Cardiovascular – NeuroBioPharm Inc.: Neurological
• Cosmeceuticals / Cosmetics
• Animal Nutrition / Pet Foods
extraction platform
Krill
• Most abundant marine biomass
• Zooplankton
• Bottom of the food chain
• Breeding in the pure uncontaminated deep sea waters
sustainability:
• Standing stock of more than 500 million tons
• Precautionary catch limit of Antarctic krill set by the CCAMLR* reviewed annually.
• Under exploited marine biomass: – Less than 0.02% is actually harvested
* CCAMLR: Commission for the Conservation of Antarctic Marine Living Resources.
teChNiCal Features
Abundant Source
• GMP Nutraceutical (NHPD / Health Canada)
• Proprietary / Patented extraction platform
• Exploit the full value of marine biomass
• Preserve biological properties
• Cold temperature / Inert environment
• Food grade organic solvent (undetected in final product)
• R&D and Laboratory Facilities in house
• Fine Point Production Technology
NeptuNe Krill Oil (NKO®
)
Brunswick Laboratories, 6 Thachet Lane, Wareham, MA 02571
Boxin Ou, Principal Research Scientist U.S. Departement of Agriculture (http://www.ars.usda.gouv/nutrientdata)
8
11
51
58
96
147
378
Fish Oil
co-q10
Astaxanthin
Lycopene
Blueberry
Cranberry
Elderberry
4003002001000
66
OR
AC
Va
lue nko® Astaxanthin:
> 90% esterified
A proprietary marine extract, offering a unique composition of EPA & DHA functionalized on PHOSPHOLIPIDS and esterified ASTAXANTHIN.
Patented composition
highest Omega-3 Bioavailability
Superior Antioxidant Potency
Design: Human Study, Perspective, Randomized, Double BlindDosage: Standardized to 120 mg of EPA & DHA / dayresults: NKO® demonstrates a greater increase of Omega-3 Index
and provides higher bioavailability of EPA & DHA compared to other sources of Omega-3
*Omega-3 Index: New Risk Factor for cardiovascular diseases. Indicates the amount of EPA & DHA in red blood cells versus total fatty acids. Closer to 8 = lower risk for cardio diseases
Baseline 8 weeks 16 weeks
6,67*
5,955,98
6,27
5,93
6,056,2
5,80
6,69*
5,16
5,675,81*
7
5
6,6
6,2
5,8
5,4
Omega-3 Index*N = 48
Om
eg
a-3
Ind
ex
Ethyl Esters
Fish Oil
NKO®-like Blend
Oxygen radical absorption Capacity
Your Only Choice !
Neptune Technologies & Bioressources has gained over the last decade, significant expertise on the research, innovation, development, scientific validation and commercialization of proprietary/patent protected natural health ingredients with worldwide regulatory approvals.
The Company pursues market opportunities in nutraceutical and pharmaceutical industries focusing on growing therapeutic indications such as heart, joint and cognitive health.
Neptune is the pioneer in the research, development and commercialization of krill extracts for human health benefits. The Company’s first product is the globally acknowledged
Neptune Krill Oil (NKO®).
NeptuNe teChNOlOgies & BiOressOurCes iNC.
www.neptunebiotech.com Tél.: +1 450 687-2262 Email: [email protected]
• Identify & Exploit Marine Biomass
• Research & Develop Novel Marine Bioactive Ingredients and Customized Formulations
• Validate Superiority, Safety & Effectiveness
• Protect Intellectual Property
• Commercialize / Pursue opportunities in Nutraceutical & Pharmaceutical Markets
• Develop Strategic Partnerships with industry leaders
Mission
Markets• Dietary Supplements
• Complementary Medicine
• Functional Food
• Pharmaceuticals via subsidiaries – Acasti Pharma Inc.: Cardiovascular – NeuroBioPharm Inc.: Neurological
• Cosmeceuticals / Cosmetics
• Animal Nutrition / Pet Foods
extraction platform
Krill
• Most abundant marine biomass
• Zooplankton
• Bottom of the food chain
• Breeding in the pure uncontaminated deep sea waters
sustainability:
• Standing stock of more than 500 million tons
• Precautionary catch limit of Antarctic krill set by the CCAMLR* reviewed annually.
• Under exploited marine biomass: – Less than 0.02% is actually harvested
* CCAMLR: Commission for the Conservation of Antarctic Marine Living Resources.
teChNiCal Features
Abundant Source
• GMP Nutraceutical (NHPD / Health Canada)
• Proprietary / Patented extraction platform
• Exploit the full value of marine biomass
• Preserve biological properties
• Cold temperature / Inert environment
• Food grade organic solvent (undetected in final product)
• R&D and Laboratory Facilities in house
• Fine Point Production Technology
NeptuNe Krill Oil (NKO®
)
Brunswick Laboratories, 6 Thachet Lane, Wareham, MA 02571
Boxin Ou, Principal Research Scientist U.S. Departement of Agriculture (http://www.ars.usda.gouv/nutrientdata)
8
11
51
58
96
147
378
Fish Oil
co-q10
Astaxanthin
Lycopene
Blueberry
Cranberry
Elderberry
4003002001000
66
OR
AC
Va
lue nko® Astaxanthin:
> 90% esterified
A proprietary marine extract, offering a unique composition of EPA & DHA functionalized on PHOSPHOLIPIDS and esterified ASTAXANTHIN.
Patented composition
highest Omega-3 Bioavailability
Superior Antioxidant Potency
Design: Human Study, Perspective, Randomized, Double BlindDosage: Standardized to 120 mg of EPA & DHA / dayresults: NKO® demonstrates a greater increase of Omega-3 Index
and provides higher bioavailability of EPA & DHA compared to other sources of Omega-3
*Omega-3 Index: New Risk Factor for cardiovascular diseases. Indicates the amount of EPA & DHA in red blood cells versus total fatty acids. Closer to 8 = lower risk for cardio diseases
Baseline 8 weeks 16 weeks
6,67*
5,955,98
6,27
5,93
6,056,2
5,80
6,69*
5,16
5,675,81*
7
5
6,6
6,2
5,8
5,4
Omega-3 Index*N = 48
Om
eg
a-3
Ind
ex
Ethyl Esters
Fish Oil
NKO®-like Blend
Oxygen radical absorption Capacity
